{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:22:16Z","timestamp":1783164136219,"version":"3.54.6"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The natural fate of chronic kidney disease (CKD) is the progression to dialysis; however, most patients face fatal and nonfatal cardiovascular events throughout their lifetime. We here address the role of low-density lipoprotein cholesterol (LDL-C) in the excess cardiovascular risk and the impact of traditional and innovative LDL-lowering therapies across the whole spectrum of CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Current guidelines on the prevention of atherosclerotic cardiovascular disease (ASCVD) from European and US cardiology societies recommend the assessment of total cardiovascular disease risk to modulate the intensity of preventive strategies in relation to the cardiovascular risk of patients: the higher the cardiovascular risk, the more intense should be the intervention. New drugs have demonstrated efficacy in achieving the lower LDL-C goals not attained by traditional therapy. The detection of vulnerable coronary plaque, rather than merely be the presence of luminal narrowing, provides an attractive imaging target to guide intensified preventive strategies in high-risk population including patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>In the context of CKD, the patient journey represents a dynamic, longitudinal care pathway in which cardiovascular risk progressively increases in parallel with declining renal function. Despite clear recommendations from nephrology and non-nephrology guidelines, treatment initiation, maintenance and intensification as well as LDL-C target are frequently overlooked in CKD population. Since novel LDL-lowering therapies provide additional therapeutic options for the patients with CKD, it is today mandatory to raise awareness on cardiovascular risk and to integrate lipid management into the broader, longitudinal care of patients with CKD across all stages of disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-026-01434-y","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:29:21Z","timestamp":1783157361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments"],"prefix":"10.1007","volume":"28","author":[{"given":"Roberto","family":"Minutolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Lullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"7","key":"1434_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41581-024-00829-x","volume":"20","author":"Kidney disease","year":"2024","unstructured":"Kidney disease. a global health priority. Nat Rev Nephrol. 2024;20(7):421\u20133.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"1434_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41581-025-00978-7","volume":"21","author":"P Pais","year":"2025","unstructured":"Pais P, Luyckx V, Chatterjee S, Essue BM. The catastrophic costs of chronic kidney disease. Nat Rev Nephrol. 2025;21(9):580\u20131.","journal-title":"Nat Rev Nephrol"},{"issue":"10440","key":"1434_CR3","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204\u201356.","journal-title":"Lancet"},{"issue":"4","key":"1434_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/1573403X10666140214122234","volume":"9","author":"Q Cai","year":"2013","unstructured":"Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013;9(4):331\u20139.","journal-title":"Curr Cardiol Rev"},{"key":"1434_CR5","doi-asserted-by":"crossref","unstructured":"Sarnak MJ, Amann K, Bangalore S et al. Conference Participants. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(14):1823\u20131838.","DOI":"10.1016\/j.jacc.2019.08.1017"},{"issue":"6","key":"1434_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.31083\/j.rcm2506200","volume":"30","author":"S Barbuto","year":"2024","unstructured":"Barbuto S, Hu L, Abenavoli C, et al. Coronary Artery Disease in Patients Undergoing Hemodialysis: A Problem that Sounds the Alarm. Rev Cardiovasc Med. 2024;30(6):200.","journal-title":"Rev Cardiovasc Med"},{"issue":"9844","key":"1434_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli M, Muntner P, Lloyd A, et al. Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807\u201314.","journal-title":"Lancet"},{"issue":"3","key":"1434_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.ajkd.2014.03.013","volume":"64","author":"M Tonelli","year":"2014","unstructured":"Tonelli M, Muntner P, Lloyd A, et al. Alberta Kidney Disease Network. Impact of age on the association between CKD and the risk of future coronary events. Am J Kidney Dis. 2014;64(3):375\u201382.","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"1434_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"ME Grams","year":"2023","unstructured":"Grams ME, Coresh J, Matsushita K, Writing Group for the CKD Prognosis Consortium, et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. JAMA. 2023;330(13):1266\u201377.","journal-title":"JAMA"},{"issue":"1","key":"1434_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.kint.2025.10.004","volume":"109","author":"N Tangri","year":"2026","unstructured":"Tangri N, Neuen BL, Cherney DZ, Tuttle KR, Perkovic V. From progression to remission: a new paradigm for success in chronic kidney disease. Kidney Int. 2026;109(1):17\u201321.","journal-title":"Kidney Int"},{"issue":"10302","key":"1434_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802.","journal-title":"Lancet"},{"issue":"14","key":"1434_CR12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacc.2024.06.041","volume":"84","author":"T Geng","year":"2024","unstructured":"Geng T, Xu W, Gao H, et al. Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults. J Am Coll Cardiol. 2024;84(14):1313\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1434_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1681\/ASN.2012080870","volume":"24","author":"M Tonelli","year":"2013","unstructured":"Tonelli M, Muntner P, Lloyd A, Manns B, et al. Alberta Kidney Disease Network. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24(6):979\u201386.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1434_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.numecd.2015.04.001","volume":"25","author":"L De Nicola","year":"2015","unstructured":"De Nicola L, Provenzano M, Chiodini P, et al. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy. Nutr Metab Cardiovasc Dis. 2015;25(8):756\u201362.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"1434_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, ESC Scientific Document Group, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"1434_CR16","doi-asserted-by":"publisher","unstructured":"Members WC, Blumenthal RS, Morris PB et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online March 13, 2026. https:\/\/doi.org\/10.1161\/CIR.0000000000001423","DOI":"10.1161\/CIR.0000000000001423"},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46:4359\u201378.","journal-title":"Eur Heart J"},{"issue":"4S","key":"1434_CR18","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.","journal-title":"BMJ"},{"key":"1434_CR20","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","volume":"27","author":"K Matsushita","year":"2020","unstructured":"Matsushita K, Jassal SK, Sang Y, et al. Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. EClinicalMedicine. 2020;27:100552.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"1434_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association\u2019s PREVENT Equations. Circulation. 2024;149(6):430\u201349.","journal-title":"Circulation"},{"key":"1434_CR22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/kisup.2013.27","volume":"3","author":"Kidney Disease","year":"2013","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney inter Suppl. 2013;3:259\u2013305.","journal-title":"Kidney inter Suppl"},{"issue":"9","key":"1434_CR23","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.3390\/nu13093138","volume":"13","author":"Z Kochan","year":"2021","unstructured":"Kochan Z, Szupryczynska N, Malgorzewicz S, Karbowska J. Dietary lipids and dyslipidemia in chronic kidney disease. Nutrients. 2021;13(9):3138.","journal-title":"Nutrients"},{"issue":"22","key":"1434_CR24","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","volume":"42","author":"T Speer","year":"2021","unstructured":"Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J. 2021;42(22):2170\u201385.","journal-title":"Eur Heart J"},{"issue":"8","key":"1434_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41581-021-00423-5","volume":"17","author":"H Noels","year":"2021","unstructured":"Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021;17(8):528\u201342.","journal-title":"Nat Rev Nephrol"},{"issue":"19","key":"1434_CR26","doi-asserted-by":"publisher","first-page":"9664","DOI":"10.3390\/ijms26199664","volume":"26","author":"C Secondulfo","year":"2025","unstructured":"Secondulfo C, Izzo C, Vecchione N, et al. Apolipoproteins in chronic kidney disease and kidney transplant: a long unfinished story. Int J Mol Sci. 2025;26(19):9664.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1434_CR27","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.7150\/ijms.114382","volume":"22","author":"D Zha","year":"2025","unstructured":"Zha D, Gao P, Wu X. Role of metabolic abnormalities during the progression of chronic kidney disease and preventive strategies. Int J Med Sci. 2025;22(14):3543\u201355.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1434_CR28","first-page":"e21506","volume":"14","author":"M Saini","year":"2022","unstructured":"Saini M, Vamne A, Kumar V, Chandel MS. The study of pattern of lipid profile in chronic kidney disease patients on conservative management and hemodialysis: a comparative study. Cureus. 2022;14(1):e21506.","journal-title":"Cureus"},{"issue":"6","key":"1434_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.0894-0959.2004.17610.x","volume":"17","author":"J Burkart","year":"2004","unstructured":"Burkart J. Metabolic consequences of peritoneal dialysis. Semin Dial. 2004;17(6):498\u2013504.","journal-title":"Semin Dial"},{"issue":"9","key":"1434_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1159\/000518456","volume":"52","author":"P Theofilis","year":"2021","unstructured":"Theofilis P, Vordoni A, Koukoulaki M, et al. Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives. Am J Nephrol. 2021;52(9):693\u2013701.","journal-title":"Am J Nephrol"},{"issue":"10","key":"1434_CR31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"WG Collaboration, Herrington","year":"2016","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT), Collaboration, Herrington WG, Emberson J, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4(10):829\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1434_CR32","first-page":"CD007784","volume":"11","author":"DJ Tunnicliffe","year":"2023","unstructured":"Tunnicliffe DJ, Palmer SC, Cashmore BA, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023;11(11):CD007784.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9784","key":"1434_CR33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"10","key":"1434_CR34","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1681\/ASN.2016090957","volume":"28","author":"JW Stanifer","year":"2017","unstructured":"Stanifer JW, Charytan DM, White J, et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. J Am Soc Nephrol. 2017;28(10):3034\u201343.","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"1434_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1434_CR36","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"4","key":"1434_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","volume":"73","author":"M Szarek","year":"2019","unstructured":"Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73(4):387\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1434_CR38","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019;73(23):2961\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"1434_CR39","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93:1397\u2013408.","journal-title":"Kidney Int"},{"issue":"42","key":"1434_CR40","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","volume":"41","author":"J Tu\u00f1\u00f3n","year":"2020","unstructured":"Tu\u00f1\u00f3n J, Steg PG, Bhatt DL, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020;41(42):4114\u201323.","journal-title":"Eur Heart J"},{"issue":"1","key":"1434_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2020;95(1):77\u201389.","journal-title":"Mayo Clin Proc"},{"key":"1434_CR42","doi-asserted-by":"publisher","unstructured":"Landmesser U, Ray KK, Raal FJ, et al. Inclisiran in patients with CKD: post hoc pooled analysis of three phase 3 trials. J Am Soc Nephrol Published online January. 2026;28. https:\/\/doi.org\/10.1681\/ASN.0000001006.","DOI":"10.1681\/ASN.0000001006"},{"key":"1434_CR43","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.","journal-title":"Nat Commun"},{"issue":"15","key":"1434_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"6","key":"1434_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-025-02158-0","volume":"85","author":"D Tramontano","year":"2025","unstructured":"Tramontano D, Bini S, Maiorca C, et al. Renal safety assessment of lipid-lowering drugs: between old certainties and new questions. Drugs. 2025;85(6):755\u201375.","journal-title":"Drugs"},{"issue":"17","key":"1434_CR46","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154\u201369.","journal-title":"Circulation"},{"key":"1434_CR47","doi-asserted-by":"crossref","unstructured":"Johansen KL, Gilbertson DT, Li S, et al. Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2024;83(4 Suppl 1):A8\u201313. US Renal Data System 2023 Annual Data Report:.","DOI":"10.1053\/j.ajkd.2024.01.001"},{"issue":"12","key":"1434_CR48","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/toxins8120376","volume":"8","author":"N Florens","year":"2016","unstructured":"Florens N, Calzada C, Lyasko E, Juillard L, Soulage CO. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel). 2016;8(12):376.","journal-title":"Toxins (Basel)"},{"issue":"4","key":"1434_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.291.4.451","volume":"291","author":"Y Liu","year":"2004","unstructured":"Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291(4):451\u20139.","journal-title":"JAMA"},{"issue":"suppl3","key":"1434_CR50","doi-asserted-by":"publisher","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","volume":"33","author":"M Cozzolino","year":"2018","unstructured":"Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transpl. 2018;33(suppl3):iii28\u201334.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"1434_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348.","journal-title":"N Engl J Med"},{"issue":"14","key":"1434_CR52","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, AURORA Study Group, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"issue":"6","key":"1434_CR53","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2215\/CJN.09121010","volume":"6","author":"W M\u00e4rz","year":"2011","unstructured":"M\u00e4rz W, Genser B, Drechsler C, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6(6):1316\u201325.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1434_CR54","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/ASN.2010090987","volume":"22","author":"H Holdaas","year":"2011","unstructured":"Holdaas H, Holme I, Schmieder RE, et al. AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011;22(7):1335\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1434_CR55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1056\/NEJMoa2513032","volume":"394","author":"CE Lok","year":"2026","unstructured":"Lok CE, Farkouh M, Hemmelgarn BR, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2026;394(2):128\u201337.","journal-title":"N Engl J Med"},{"issue":"21","key":"1434_CR56","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1161\/CIR.0000000000001104","volume":"146","author":"XS Cheng","year":"2022","unstructured":"Cheng XS, VanWagner LB, Costa SP, et al. Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation. Circulation. 2022;146(21):e299\u2013324.","journal-title":"Circulation"},{"key":"1434_CR57","doi-asserted-by":"publisher","unstructured":"Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2009;(1):CD005632. https:\/\/doi.org\/10.1002\/14651858.CD005632.","DOI":"10.1002\/14651858.CD005632"},{"issue":"1","key":"1434_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/MNH.0000000000000841","volume":"32","author":"P Skulratanasak","year":"2023","unstructured":"Skulratanasak P, Larpparisuth N. Lipid management to mitigate poorer postkidney transplant outcomes. Curr Opin Nephrol Hypertens. 2023;32(1):27\u201334.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9374","key":"1434_CR59","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024\u201331.","journal-title":"Lancet"},{"issue":"12","key":"1434_CR60","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","volume":"5","author":"H Holdaas","year":"2005","unstructured":"Holdaas H, Fellstr\u00f6m B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transpl. 2005;5(12):2929\u201336.","journal-title":"Am J Transpl"},{"issue":"1","key":"1434_CR61","first-page":"CD005019","volume":"2014","author":"SC Palmer","year":"2014","unstructured":"Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014;2014(1):CD005019.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1434_CR62","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1600-6143.2006.01263.x","volume":"6","author":"C Buchanan","year":"2006","unstructured":"Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transpl. 2006;6(4):770\u20134.","journal-title":"Am J Transpl"},{"issue":"8","key":"1434_CR63","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830\u20133.","journal-title":"Eur Heart J"},{"issue":"5","key":"1434_CR64","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1097\/TP.0000000000004942","volume":"108","author":"JM Amaro","year":"2024","unstructured":"Amaro JM, Villanego F, Orellana CD, et al. Management of dyslipidemia with evolocumab in kidney transplant recipients. Transplantation. 2024;108(5):e74\u20136.","journal-title":"Transplantation"},{"issue":"34","key":"1434_CR65","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"5","key":"1434_CR66","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/ckj\/sfz095","volume":"13","author":"P Kouis","year":"2019","unstructured":"Kouis P, Kousios A, Kanari A, Kleopa D, Papatheodorou SI, Panayiotou AG. Association of non-invasive measures of subclinical atherosclerosis and arterial stiffness with mortality and major cardiovascular events in chronic kidney disease: systematic review and meta-analysis of cohort studies. Clin Kidney J. 2019;13(5):842\u201354.","journal-title":"Clin Kidney J"},{"issue":"6","key":"1434_CR67","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1007\/s12350-020-02080-w","volume":"28","author":"C Wenning","year":"2021","unstructured":"Wenning C, Vrachimis A, Pavenst\u00e4dt HJ, Reuter S, Sch\u00e4fers M. Coronary artery calcium burden, carotid atherosclerotic plaque burden, and myocardial blood flow in patients with end-stage renal disease: A non-invasive imaging study combining PET\/CT and 3D ultrasound. J Nucl Cardiol. 2021;28(6):2660\u201370.","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"1434_CR68","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","volume":"2","author":"J Chen","year":"2017","unstructured":"Chen J, Budoff MJ, Reilly MP, et al. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol. 2017;2(6):635\u201343.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"1434_CR69","doi-asserted-by":"publisher","first-page":"e017066","DOI":"10.1161\/CIRCIMAGING.124.017066","volume":"17","author":"JN Dahl","year":"2024","unstructured":"Dahl JN, Nielsen MB, Rasmussen LD, et al. Coronary Plaque Characteristics in Patients With Chronic Kidney Failure: Impact on Cardiovascular Events and Mortality. Circ Cardiovasc Imaging. 2024;17(10):e017066.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"1434_CR70","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/ATVBAHA.119.312705","volume":"39","author":"JM Valdivielso","year":"2019","unstructured":"Valdivielso JM, Rodr\u00edguez-Puyol D, Pascual J, et al. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arterioscler Thromb Vasc Biol. 2019;39(10):1938\u201366.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1434_CR71","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jcmg.2024.12.004","volume":"18","author":"R Vergallo","year":"2025","unstructured":"Vergallo R, Park SJ, Stone GW, et al. Vulnerable or High-Risk Plaque: A JACC: Cardiovascular Imaging Position Statement. JACC Cardiovasc Imaging. 2025;18(6):709\u201340.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1434_CR72","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2017.12.007","volume":"72","author":"LP Gregg","year":"2018","unstructured":"Gregg LP, Hedayati SS. Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data? Am J Kidney Dis. 2018;72(5):728\u201344.","journal-title":"Am J Kidney Dis"},{"key":"1434_CR73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejim.2024.08.010","volume":"129","author":"A Cesaro","year":"2024","unstructured":"Cesaro A, Acerbo V, Indolfi C, Filardi PP, Calabr\u00f2 P. The clinical relevance of the reversal of coronary atherosclerotic plaque. Eur J Intern Med. 2024;129:16\u201324.","journal-title":"Eur J Intern Med"},{"issue":"22","key":"1434_CR74","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"18","key":"1434_CR75","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771\u201381.","journal-title":"JAMA"},{"issue":"7","key":"1434_CR76","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1434_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jacl.2025.10.066","volume":"20","author":"A Cesaro","year":"2026","unstructured":"Cesaro A, Acerbo V, Scialla F, et al. Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy. J Clin Lipidol. 2026;20(1):66\u201374.","journal-title":"J Clin Lipidol"},{"key":"1434_CR78","doi-asserted-by":"publisher","unstructured":"Cesaro A, Pastori D, Acerbo V, et al. Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An updated systematic review and meta regression analysis of randomized controlled trials. Eur J Prev Cardiol Published online April. 2025;28. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf257.","DOI":"10.1093\/eurjpc\/zwaf257"},{"key":"1434_CR79","doi-asserted-by":"publisher","unstructured":"Cesaro A, Acerbo V, Longo M, et al. Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials. Eur J Prev Cardiol Published online Febr. 2026;9. https:\/\/doi.org\/10.1093\/eurjpc\/zwag077.","DOI":"10.1093\/eurjpc\/zwag077"},{"issue":"7","key":"1434_CR80","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","volume":"3","author":"K Matsushita","year":"2015","unstructured":"Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514\u201325.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1434_CR81","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"issue":"12","key":"1434_CR82","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro CJ, Mark PB, Kanbay M, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727\u201349.","journal-title":"Nat Rev Nephrol"},{"key":"1434_CR83","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol. 2006;290:F262\u2013272.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1","key":"1434_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","volume":"22","author":"V Calice-Silva","year":"2023","unstructured":"Calice-Silva V, Muenz D, Wong MMY, et al. International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations? Lipids Health Dis. 2023;22(1):67.","journal-title":"Lipids Health Dis"},{"issue":"4S1 Suppl 1","key":"1434_CR85","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","volume":"104","author":"SJ Chadban","year":"2020","unstructured":"Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1 Suppl 1):S11\u2013103.","journal-title":"Transplantation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01434-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01434-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01434-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:02:41Z","timestamp":1783162961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01434-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01434-y","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Roberto Minutolo has been member of Advisory Boards for Amgen, Astellas, Bayer, Boehringer and invited speaker at meetings supported by Amgen, Astellas, Astra Zeneca, Bayer, Boehringer Novo Nordisk, CSL Vifor, and support for attending meetings from Amgen. Luca De Nicola has received fees from Astra Zeneca for lectures, consulting fees from Bayer, and support for attending meetings from Amgen Arturo Cesaro has been member of Advisory Boards for Amgen, Sanofi, Novartis, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Chiesi, Sharper, and Amarin and invited speaker at meetings supported by Novo Nordisk and Amgen, and support for attending meetings from Menarini, Daiichi Sankyo, and Novartis. Mario Cozzolino has been member of Advisory Boards for Amgen, Novo Nordisk, CSL Vifor and Boehringer and invited speaker at meetings supported by Amgen, Astellas, Astra Zeneca, Bayer, Boehringer, CSL Vifor Luca Di Lullo: has been invited speaker by Astellas, Amgen and Eli Lilly Massimo Iacoviello: has been member of Advisory Boards for Boehringer, Eli Lilly, Novo Nordisk and invited speaker at meetings supported by Astra Zeneca, Bayer, Boehringer, Bruno Farmaceutici, Eli Lilly, Neopharmed Gentili, Novo Nordisk. Ernesto Paoletti has been member of Advisory Boards for Boehringer, and CSL Vifor, and invited speaker at meetings supported by Amgen, Astellas, Astra Zeneca, and Novartis. Maura Ravera has been member of Advisory Boards for Amgen, GSK, Boehringer and invited speaker at meetings supported by Amgen, Astellas, Astra Zeneca, Boehringer, CSL Vifor. Vincenzo Russo: None to declare","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"68"}}